Remission in major depression with two antidepressant mechanisms: Results from a naturalistic study

Journal of Affective Disorders

Volumn 79, Issue 1-3, 2004, Pages 229-234

  Montes, José Manuel ^a,d   Ferrando, Laura ^b   Saiz Ruiz, Jerónimo ^c  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b Instituto IAP   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d CSM 'La Plata'   (Spain)

Author keywords

Antidepressant; Depression; Noradrenaline; Remission; Serotonin

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG CONTRAINDICATION; DRUG MECHANISM; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MAJOR DEPRESSION; MALE; MEDICAL ASSESSMENT; MELANCHOLIA; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 1542613960     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(02)00353-1     Document Type: Article

References (21)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition :1987;APA, Washington, DC.
2. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8:1994;238-249.
3. Beasley C.M. Jr., Holman S.L., Potvin J.H. Fluoxetine compared with imipramine in the treatment of inpatient depression: a multicenter trial. Ann. Clin. Psychiatry. 5:1993;199-207.
4. Clinical Practice Guideline No. 5. Depression in Primary Care. Vol. 2:1993;US Dept Health Human Services, Agency for Health Care Policy and Research. AHCPR publication 93-0551, Rockville, MD.
5. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology. 90:1986;131-138.
6. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18:1990;289-299.
7. Donovan S.J., Quitkin F.M., Stewart J.W., Ocepek-Welikson K., Harrison W., McGrath P.J., Nunes E.V., Wager S., Tricamo E. Duration of antidepressant trials: clinical and research implications. J. Clin. Psychopharmacol. 14:1994;64-66.
8. Faravelli C., Ambonetti A., Pallanti S., Pazzagli A. Depressive relapses and incomplete recovery from an index episode. Am. J. Psychiatry. 143:1986;888-891.
9. Feighner J.P., Cohn J.B., Fabre L.F. Jr., Fieve R.R., Mendels J., Shrivastava R.K., Dunbar G.C. A study comparing paroxetine, placebo, and imipramine in depressed patients. J. Affect. Disord. 28:1993;71-79.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
11. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B. Major depressive disorder: a prospective study of subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord. 50:1998;97-108.
12. Judd L.L., Akiskal H.S., Paulus M.P. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J. Affect. Disord. 45:1997;5-18.
13. Maier W., Gansicke M., Weiffenbach O. The relationship between major and subthreshold variants of unipolar depression. J. Affect. Disord. 45:1997;41-51.
14. Mintz J., Mintz L.I., Arruda M.J., Hwang S.S. Treatments of depression and the functional capacity to work. Arch. Gen. Psychiatry. 49:1992;761-768.
15. Nelson C., Mazure C.M., Bowers M.B. Jr., Jatlow P.I. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry. 48:1991;303-307.
16. Nierenberg A.A., McLean N.E., Alpert J.E., Worthington J.J., Rosenbaum J.F., Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry. 152:1995;1500-1503.
17. Nierenberg A.A., Wright E.C. Evolution of remission as the new standard in the treatment of depression. J. Clin. Psychiatry. 60:(Suppl. 22):1999;7-11.
18. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25:1995;1171-1180.
19. Roose R.P., Glassman A.H., Attia E., Woodring S. Comparative efficacy of the selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry. 151:1994;1735-1739.
20. Seth R., Jennings A.L., Bindman J., Phillips J., Bergmann K. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br. J. Psychiatry. 161:1992;562-565.
21. Thase M.E., Entsuah R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry. 178:2001;234-241.